(BTSG) BrightSpring Health - Overview
Sector: Healthcare | Industry: Health Information Services | Exchange: NASDAQ (USA) | Market Cap: 11.325m USD | Total Return: 141.1% in 12m
Home Health, Pharmacy Services, Rehabilitation, Behavioral Therapy
Total Rating 75
Safety 77
Buy Signal 1.68
Health Information Services
Industry Rotation: +11.2
Industry Rotation: +11.2
Market Cap:
11.3B
Avg Turnover: 120M
Avg Turnover: 120M
Risk 3d forecast
Volatility43.1%
VaR 5th Pctl7.23%
VaR vs Median1.93%
Reward TTM
Sharpe Ratio2.29
Rel. Str. IBD95.3
Rel. Str. Peer Group98.2
Character TTM
Beta1.351
Beta Downside0.885
Hurst Exponent0.298
Drawdowns 3y
Max DD35.56%
CAGR/Max DD3.00
CAGR/Mean DD14.74
EPS (Earnings per Share)
EPS CAGR: 57.67%
EPS Trend: 76.9%
EPS Trend: 76.9%
Last SUE: 1.10
Qual. Beats: 2
Qual. Beats: 2
Revenue
Rev. CAGR: 18.96%
Rev. Trend: 98.2%
Rev. Trend: 98.2%
Last SUE: 1.72
Qual. Beats: 4
Qual. Beats: 4
Warnings
P/E ratio 75.8
Tailwinds
Supp Ema8, Supp Ema20, Leader, Tailwind, Confidence
Description: BTSG BrightSpring Health
BrightSpring Health Services (BTSG) is a provider of home and community-based healthcare services in the United States, operating through its Pharmacy Solutions and Provider Services segments. The company manages a range of clinical and supportive care for Medicare, Medicaid, and private insurance populations, specializing in medication management, home health, and rehabilitation therapies. As the U.S. population ages, the home healthcare sector is increasingly prioritized by payers to reduce high-cost hospital stays and improve patient outcomes through long-term management of chronic conditions.
The business model integrates pharmacy logistics with direct clinical care, allowing for coordination between medication delivery and physical or behavioral therapy. This vertically integrated approach is common among large-scale healthcare platforms seeking to capture value across multiple touchpoints in the patient journey. For a deeper look into the companys valuation metrics and historical performance, consider reviewing the data on ValueRay.
Founded in 1974 and headquartered in Louisville, Kentucky, the company rebranded from Phoenix Parent Holdings in 2021. Its service portfolio includes specialty medication administration such as infused and injectable treatments, alongside specialized behavioral analysis and occupational therapy.
- Pharmacy Solutions volume growth drives high-margin specialty medication revenue
- Expansion of home-based provider services captures aging demographic healthcare demand
- Medicaid and Medicare reimbursement rate changes impact consolidated operating margins
- High debt leverage increases sensitivity to federal interest rate policy shifts
- Labor cost inflation and clinical staffing shortages pressure provider segment profitability
Piotroski VR‑10 (Strict)
6.5
| Net Income: 235.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 4.45 > 1.0 |
| NWC/Revenue: 8.36% < 20% (prev 9.50%; Δ -1.14% < -1%) |
| CFO/TA 0.08 > 3% & CFO 511.5m > Net Income 235.6m |
| Net Debt (1.81b) to EBITDA (627.3m): 2.89 < 3 |
| Current Ratio: 1.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (221.3m) vs 12m ago 2.97% < -2% |
| Gross Margin: 12.18% > 18% (prev 0.13%; Δ 1.20k% > 0.5%) |
| Asset Turnover: 226.3% > 50% (prev 192.9%; Δ 33.45% > 0%) |
| Interest Coverage Ratio: 3.02 > 6 (EBITDA TTM 627.3m / Interest Expense TTM 154.2m) |
Altman Z''
1.74
| A: 0.18 (Total Current Assets 2.69b - Total Current Liabilities 1.55b) / Total Assets 6.21b |
| B: 0.00 (Retained Earnings 14.1m / Total Assets 6.21b) |
| C: 0.08 (EBIT TTM 466.1m / Avg Total Assets 6.03b) |
| D: 0.00 (Book Value of Equity 14.8m / Total Liabilities 4.22b) |
| Altman-Z'' Score: 1.74 = BBB |
Beneish M
-2.97
| DSRI: 0.86 (Receivables 1.11b/1.07b, Revenue 13.65b/11.28b) |
| GMI: 1.08 (GM 12.18% / 13.13%) |
| AQI: 0.99 (AQ_t 0.51 / AQ_t-1 0.51) |
| SGI: 1.21 (Revenue 13.65b / 11.28b) |
| TATA: -0.04 (NI 235.6m - CFO 511.5m) / TA 6.21b) |
| Beneish M-Score: -2.97 (Cap -4..+1) = A |
What is the price of BTSG shares?
As of May 16, 2026, the stock is trading at USD 57.90 with a total of 2,833,365 shares traded.
Over the past week, the price has changed by +5.60%, over one month by +25.84%, over three months by +50.55% and over the past year by +141.05%.
Over the past week, the price has changed by +5.60%, over one month by +25.84%, over three months by +50.55% and over the past year by +141.05%.
Is BTSG a buy, sell or hold?
BrightSpring Health has received a consensus analysts rating of 4.67.
Therefore, it is recommended to buy BTSG.
- StrongBuy: 9
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BTSG price?
| Analysts Target Price | 60.5 | 4.5% |
BrightSpring Health (BTSG) - Fundamental Data Overview
as of 16 May 2026
P/E Trailing = 75.8442 P/E Forward = 40.6504
P/S = 0.8299
P/B = 5.3718
Revenue TTM = 13.65b USD
EBIT TTM = 466.1m USD
EBITDA TTM = 627.3m USD
Long Term Debt = 2.44b USD (from longTermDebt, last quarter)
Short Term Debt = 105.1m USD (from shortTermDebt, last quarter)
Debt = 2.70b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.81b USD (from netDebt column, last quarter)
Enterprise Value = 13.14b USD (11.32b + Debt 2.70b - CCE 888.8m)
Interest Coverage Ratio = 3.02 (Ebit TTM 466.1m / Interest Expense TTM 154.2m)
EV/FCF = 31.87x (Enterprise Value 13.14b / FCF TTM 412.1m)
FCF Yield = 3.14% (FCF TTM 412.1m / Enterprise Value 13.14b)
FCF Margin = 3.02% (FCF TTM 412.1m / Revenue TTM 13.65b)
Net Margin = 1.73% (Net Income TTM 235.6m / Revenue TTM 13.65b)
Gross Margin = 12.18% ((Revenue TTM 13.65b - Cost of Revenue TTM 11.98b) / Revenue TTM)
Gross Margin QoQ = 13.34% (prev 11.62%)
Tobins Q-Ratio = 2.11 (Enterprise Value 13.14b / Total Assets 6.21b)
Interest Expense / Debt = 1.43% (Interest Expense 38.6m / Debt 2.70b)
Taxrate = 10.32% (8.55m / 82.8m)
NOPAT = 417.9m (EBIT 466.1m * (1 - 10.32%))
Current Ratio = 1.74 (Total Current Assets 2.69b / Total Current Liabilities 1.55b)
Debt / Equity = 1.36 (Debt 2.70b / totalStockholderEquity, last quarter 1.98b)
Debt / EBITDA = 2.89 (Net Debt 1.81b / EBITDA 627.3m)
Debt / FCF = 4.39 (Net Debt 1.81b / FCF TTM 412.1m)
Total Stockholder Equity = 1.85b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.91% (Net Income 235.6m / Total Assets 6.21b)
RoE = 12.71% (Net Income TTM 235.6m / Total Stockholder Equity 1.85b)
RoCE = 10.84% (EBIT 466.1m / Capital Employed (Equity 1.85b + L.T.Debt 2.44b))
RoIC = 9.57% (NOPAT 417.9m / Invested Capital 4.37b)
WACC = 8.91% (E(11.32b)/V(14.02b) * Re(10.73%) + D(2.70b)/V(14.02b) * Rd(1.43%) * (1-Tc(0.10)))
Discount Rate = 10.73% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 12.09%
[DCF] Terminal Value 66.63% ; FCFF base≈298.3m ; Y1≈195.8m ; Y5≈89.6m
[DCF] Fair Price = N/A (negative equity: EV 1.53b - Net Debt 1.81b = -282.6m; debt exceeds intrinsic value)
EPS Correlation: 76.92 | EPS CAGR: 57.67% | SUE: 1.10 | # QB: 2
Revenue Correlation: 98.22 | Revenue CAGR: 18.96% | SUE: 1.72 | # QB: 4
EPS current Quarter (2026-06-30): EPS=0.39 | Chg30d=+9.03% | Revisions=+60% | Analysts=13
EPS next Quarter (2026-09-30): EPS=0.44 | Chg30d=+5.46% | Revisions=+38% | Analysts=13
EPS current Year (2026-12-31): EPS=1.68 | Chg30d=+7.90% | Revisions=+78% | GrowthEPS=+67.8% | GrowthRev=+16.7%
EPS next Year (2027-12-31): EPS=2.11 | Chg30d=+8.09% | Revisions=+78% | GrowthEPS=+25.9% | GrowthRev=+13.6%
[Analyst] Revisions Ratio: +78%